Maximum quantity allowed is 999
请选择数量
CAS RN: 25812-30-0 | 產品號碼: G0368
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 57.0 to 62.0 °C |
性質
| 熔點 | 61 °C |
| 沸點 | 159 °C/0.02 mmHg |
| 溶解性（可溶於） | Methanol |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. H413 : May cause long lasting harmful effects to aquatic life. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
| RTECS # | YV7120000 |
運輸資料
| HS編碼* | 2918.99-000 |
Application
Gemfibrozil: An Antilipemic Fibrate
The fibrates, including gemfibrozil, are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. The precise mechanisms of action remain unknown, but it has been reported that the major modes of action of the fibrates as follows: VLDL catabolism by increased lipoprotein and hepatic triglyceride lipase activities; suppression of triglyceride biosynthesis by acetyl-CoA carboxylase enzyme inhibition and attenuation of cholesterol biosynthesis by inhibition of the rate-limiting HMG-CoA reductase. In 2000s, it has been reported that concomitant use of gemfibrozil with statins (in particular cerivastatin) increases the risk of rhabdomyolysis which is a serious syndrome due to a muscle injury. (The product is for research purpose only.)
References
- Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia
- Gemfibrozil: a reappraisal of its pharmacological properties and place in the management of dyslipidemia
- Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
- Gemfibrozil greatly increases plasma concentrations of cerivastatin
- Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study
- A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma
考研文獻
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。